Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF).

Full DD Report for KYKOF

Recent News from (OTC: KYKOF)

Kyowa Hakko Kogyo Co., Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Kyowa Hakko Kogyo Co., Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: February, 09 2018 14:13
Your Daily Pharma Scoop: Omeros If And Buts, Egalet's Oxycodone Success, Auris Flunks Study
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Omeros Corp Today we will cover...
Source: SeekingAlpha
Date: November, 29 2017 07:34
Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal diseases in Japan; ARDX up 13% premarket
Ardelyx (NASDAQ: ARDX ) and Kyowa Hakko Kirin ( OTCPK:KYKOF ) announces that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal dis...
Source: SeekingAlpha
Date: November, 28 2017 09:00
FDA grants priority review status to Kyowa Hakko Kirin's BLA for Mogamulizumab for the treatment of CTCL
Kyowa Hakko Kirin ( OTCPK:KYKOF )  announces that the FDA has accepted for review the Biologics License Application (BLA) for Mogamulizumab to treat Cutaneous T-cell Lymphoma (CTCL) in patients who have received at least one prior systemic therapy. More news on: Kyowa Hakko Kogyo...
Source: SeekingAlpha
Date: November, 28 2017 08:22
ArQule Is Undervalued Going Into Catalyst Events
ArQule (ARQL) is a small biopharmaceutical company (market cap: $100.97 million) engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Their pipeline consists of five clinical drug candidates (Figure 1), all of which are in biomarker-defin...
Source: SeekingAlpha
Date: October, 22 2016 10:08


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF)

Logo for Kyowa Hakko Kogyo Co., Ltd. (OTC: KYKOF)

Not available


Contact Information



Current Share Structure

  • Market Cap: $11,904,386,340 - 03/09/2018
  • Issue and Outstanding: 576,483,600 - 11/30/2011


Daily Technical Chart for (OTC: KYKOF)

Daily Technical Chart for (OTC: KYKOF)

Stay tuned for daily updates and more on (OTC: KYKOF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: KYKOF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KYKOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of KYKOF and does not buy, sell, or trade any shares of KYKOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: